GlaucoT Glaucoma Treatment Glasses in the Treatment of Primary Open-Angle Glaucoma

NCT05253534 | Completed DMC

• 1 other identifier: 2021-169
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 2

Brief Summary

Glaucoma is a chronic and progressive optic neuropathy characterized by degeneration of ganglion cells and axons with loss of visual function. It is estimated that glaucoma, which is the second cause of preventable blindness in the world, affects nearly 60 million people worldwide. The most common type of glaucoma is primary open-angle glaucoma (POAG). POAG is a chronic progressive optic neuropathy with characteristic morphological changes in the optic nerve head and retinal nerve fiber. POAG, progressive retinal ganglion cell death and visual field loss are associated with these changes. Risk factors for POAG are age, race, high intraocular pressure (IOP), family history of glaucoma, thin central corneal thickness (CCT), high myopia. IOP is the only modifiable risk factor that we can control. For this reason, the priority in the treatment of POAG has always been to reduce IOP. In glaucoma, the essential point is to preserve the damaged ganglion cell layer and therefore the visual functions. In addition to clinical examination, visual field measurements that measure functions, optical coherence tomography (OCT) thickness measurements that measure anatomical changes, and optic nerve head parameters are the most reliable methods for both diagnosis and evaluation of the efficacy of treatment. Following the results of the visual field and OCT measurements, it will be tried to determine to what extent glaucoma damage can be ceased by the developed GlaucoT glaucoma treatment glasses. In this study, it is aimed to measure the effectiveness and safety of flicker light therapy, the effectiveness of which has been investigated in the treatment of Alzheimer's previously and has clinically significant results, with the GlaucoT glaucoma treatment glasses, which was developed to cease visual field loss with patient comfort at the forefront and at a lower cost.

Conditions

Primary Open-Angle Glaucoma

Keywords

Glaucoma; Neuroprotection; Gamma Rhythm; Non-invasive; Wearable

Outcome Measures

Primary Outcomes (2)

• Frequency of the adverse events

  In our study, the safety of the GlaucoT glasses with flickering light treatment will be assessed. The purpose of the treatment is to provide neuroprotection with flickering light treatment. The primary outcome for safety of the device is the frequency of the adverse events.

  6 months

• The stabilization in visual field test

  The second outcome of the clinical trials will be the efficacy of the GlaucoT device. The differences between the patients who use GlaucoT will be compared with the ones that do not use the device under same conditions (e.g. drug use). The assessment will be based on visual field test.

  6 months

Study Arms (2)

Gamma Rhythm Stimulation Group

EXPERIMENTAL

Evaluation of the efficacy and safety of GlaucoT in patients with primary open-angle glaucoma (POAG). In this study, it was planned to investigate the effect of reducing the progression of glaucomatous damage by applying 40 Hz flicker light therapy for 1 hour a day to POAG patients. It is planned to use visual field test, measurements of retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) layer thicknesses in optical coherence tomography to investigate the effectiveness of the treatment.

Device: GlaucoT Glaucoma Treatment Device

Control Group

NO INTERVENTION

This group will be monitored without using the device.The data will be used only for comparison. Considering the sample size calculations and losses, a total of 60 patients are planned to be included in the study, with 30 patients in each group.

Interventions

GlaucoT Glaucoma Treatment Device DEVICE

In this study, flicker light therapy, the effectiveness of which was investigated in the treatment of glaucoma based on some methods used in different diseases, is described for the first time in glaucoma. Studies investigating the neurodegenerative properties of glaucoma have found similarities in the pathophysiology of Alzheimer's disease and glaucoma. 40 Hz flicker of light Alzheimer 's the positive effects on the knitted cortex have also been shown in studies. 40 Hz flicker light is aimed to reduce glaucoma and retinal ganglion cell loss due to glaucoma, by reducing neurodegeneration by decreasing amyloid and metabolite accumulation by increasing both microglial phagocytic activation effect and retinal blood flow.

Gamma Rhythm Stimulation Group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Those who have applied to the eye diseases clinic
• ≥18 years old
• Those diagnosed with primary open-angle glaucoma (POAG) before the study
• Recipients of standard drug therapy (defined in diagnostic and treatment guidelines) for POAG
• Patients deemed appropriate by the investigator to be included in the study after ophthalmological examination
• Patients who were informed about the study and agreed to participate in the study
• Those who agree to continue to use acceptable methods of contraception during the study

You may not qualify if:

• Those with a history of trauma or inflammation in their eyes
• Those who have undergone intraocular surgery or laser in the last 6 months, excluding those who have had uncomplicated cataract surgery
• Presence of any retinal or neurological disease other than glaucoma, abnormal ocular motility preventing binocular fixation (eg, nystagmus, strabismus)
• Those with corneal transplants
• Advanced disc cupping (c/d ratio 0.8 and above)
• Large and severe perimetric defects (a central perimetric residual not greater than 10 central degrees)
• Advanced visual field damage (MD above 12 db)
• Dry/wet type age-related macular degeneration in one or both eyes
• Those who have had glaucoma surgery in the past, excluding laser
• Corneal dystrophies
• High myopia (more than 6 diopters)
• Peripheral retinal degenerations with risk of retinal detachment
• Keratitis
• Those with severe dry eye syndrome
• Those with neurological disorders (eg, epilepsy)

Sponsors & Collaborators

• Glaucot Teknoloji Anonim Sirketi: lead

Study Sites (2)

Ege University Department of Ophthalmology

Izmir, 35100, Turkey (Türkiye)

Location

Manisa Celal Bayar University Department of Ophthalmology

Manisa, 45030, Turkey (Türkiye)

Location

Related Publications (2)

• Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, Adaikkan C, Canter RG, Rueda R, Brown EN, Boyden ES, Tsai LH. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016 Dec 7;540(7632):230-235. doi: 10.1038/nature20587.

  PMID: 27929004 BACKGROUND

• Samanchi R, Prakash Muthukrishnan S, Dada T, Sihota R, Kaur S, Sharma R. Altered spontaneous cortical activity in mild glaucoma: A quantitative EEG study. Neurosci Lett. 2021 Aug 10;759:136036. doi: 10.1016/j.neulet.2021.136036. Epub 2021 Jun 8.

  PMID: 34116196 BACKGROUND

Related Links

• The official webpage of the sponsor

MeSH Terms

Conditions

Glaucoma, Open-Angle; Glaucoma

Condition Hierarchy (Ancestors)

Ocular Hypertension; Eye Diseases

Study Officials

• Ozcan Kayikcioglu, Prof

  Manisa Celal Bayar University Department of Ophthalmology

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Evaluation of the efficacy and safety of GlaucoT in patients with primary open-angle glaucoma (POAG)

Study Record Dates

• First Submitted: February 2, 2022
• First Posted: February 23, 2022
• Study Start: March 1, 2022
• Primary Completion: December 30, 2023
• Study Completion: December 30, 2023
• Last Updated: November 18, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

TU (2)